Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms

Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Moe, Yonezawa, Taishi, Liu, Xiaoxiao, Asada, Shuhei, Hayashi, Yasutaka, Fukuyama, Tomofusa, Tanaka, Yosuke, Kitamura, Toshio, Goyama, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547685/
https://www.ncbi.nlm.nih.gov/pubmed/31160638
http://dx.doi.org/10.1038/s41598-019-44496-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547685/
https://www.ncbi.nlm.nih.gov/pubmed/31160638
http://dx.doi.org/10.1038/s41598-019-44496-6

Ejemplares similares